Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials
Nature Reviews Clinical Oncology, Published online: 22 April 2024; doi:10.1038/s41571-024-00895-xCertain subsets of patients with multiple myeloma or its precursor conditions are overtreated with current approaches to therapy. Herein, we highlight several key areas where we believe de-escalation of treatment is needed. Dedicated trials to assess these de-escalation approaches and urgent changes to current clinical practices are needed. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 22, 2024 Category: Cancer & Oncology Authors: Ghulam Rehman Mohyuddin Aaron M. Goodman Source Type: research
Multiparametric MRI for characterization of the tumour microenvironment
Nature Reviews Clinical Oncology, Published online: 19 April 2024; doi:10.1038/s41571-024-00891-1By combining multiple MRI sequences, each providing different but complementary information about the tumour microenvironment (TME), multiparametric MRI (mpMRI) enables non-invasive assessment of the heterogeneous features of the TME components. The authors of this Review describe the role of mpMRI in the non-invasive characterization of the TME, presenting examples of its utility in cancer detection, staging and assessment of response to therapy, and considering future applications for personalized integrated diagnostics. (Sou...
Source: Nature Reviews Clinical Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Emily Hoffmann Max Masthoff Wolfgang G. Kunz Max Seidensticker Stefanie Bobe Mirjam Gerwing Wolfgang E. Berdel Christoph Schliemann Cornelius Faber Moritz Wildgruber Source Type: research
Afami-cel provides a novel treatment option for rare sarcoma subtypes
Nature Reviews Clinical Oncology, Published online: 18 April 2024; doi:10.1038/s41571-024-00894-yAfami-cel provides a novel treatment option for rare sarcoma subtypes (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 18, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
ALND can be safely omitted for patients with sentinel-node macrometastases
Nature Reviews Clinical Oncology, Published online: 18 April 2024; doi:10.1038/s41571-024-00893-zALND can be safely omitted for patients with sentinel-node macrometastases (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 18, 2024 Category: Cancer & Oncology Authors: David Killock Source Type: research
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma
Nature Reviews Clinical Oncology, Published online: 15 April 2024; doi:10.1038/s41571-024-00890-2T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers that quantify T cell infiltration and the presence of proinflammatory TMEs associated with immune-checkpoint inhibitor (ICI) response for clinical implementation has proved challenging. Here, we highlight a study that validates a T cell-to-stroma enrichment score generated from RNA sequencing data as a novel biomarker for ICI response in patients with urothelial carcino...
Source: Nature Reviews Clinical Oncology - April 15, 2024 Category: Cancer & Oncology Authors: David H. Aggen Jonathan E. Rosenberg Source Type: research
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Nature Reviews Clinical Oncology, Published online: 10 April 2024; doi:10.1038/s41571-024-00886-yThe benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer types, some with practice-changing results; however, other phase III trials have had negative results. The authors of this Perspective discuss the variable outcomes of these trials, considering factors that account for these differences and suggesting future initiatives for improving the outcomes in patients receiving these combinations. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 10, 2024 Category: Cancer & Oncology Authors: Hung-Yang Kuo Kabir A. Khan Robert S. Kerbel Source Type: research
Nucleic acid-based drugs for patients with solid tumours
Nature Reviews Clinical Oncology, Published online: 08 April 2024; doi:10.1038/s41571-024-00883-1Nucleic acid-based therapies offer an alternative to traditional cancer treatment modalities, with promising data beginning to emerge. In this Review, the authors describe the design and development of nucleic acid-based therapies administered virally and non-virally, including discussions of the advantages and disadvantage of each approach, as well as the role of patient-specific factors such as the tumour microenvironment, and consider the most promising future research directions. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 8, 2024 Category: Cancer & Oncology Authors: Sebastian G. Huayamares David Loughrey Hyejin Kim James E. Dahlman Eric J. Sorscher Source Type: research
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
Nature Reviews Clinical Oncology, Published online: 02 April 2024; doi:10.1038/s41571-024-00889-9Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 2, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Global epidemiology of epithelial ovarian cancer
Nature Reviews Clinical Oncology, Published online: 28 March 2024; doi:10.1038/s41571-024-00881-3Ovarian cancer, accounting for 4.7% of cancer deaths in women in 2020, remains highly prevalent globally. Nonetheless, owing to changes in environmental exposures, the approach to preventive measures and disease classification, both incidence and mortality have been declining in economically developed countries since the early 2000s. Conversely, parts of Asia and eastern Europe have seen increases in the incidence of ovarian cancer over this period of time. In this Review, the authors summarize the epidemiology of ovarian cance...
Source: Nature Reviews Clinical Oncology - March 28, 2024 Category: Cancer & Oncology Authors: Penelope M. Webb Susan J. Jordan Source Type: research
Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
Nature Reviews Clinical Oncology, Published online: 25 March 2024; doi:10.1038/s41571-024-00888-wMirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 25, 2024 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Enhancing diagnostic precision in liver lesion analysis using a deep learning-based system: opportunities and challenges
Nature Reviews Clinical Oncology, Published online: 22 March 2024; doi:10.1038/s41571-024-00887-xA recent study reported the development and validation of the Liver Artificial Intelligence Diagnosis System (LiAIDS), a fully automated system that integrates deep learning for the diagnosis of liver lesions on the basis of contrast-enhanced CT scans and clinical information. This tool improved diagnostic precision, surpassed the accuracy of junior radiologists (and equalled that of senior radiologists) and streamlined patient triage. These advances underscore the potential of artificial intelligence to enhance hepatology care...
Source: Nature Reviews Clinical Oncology - March 22, 2024 Category: Cancer & Oncology Authors: Jeong Min Lee Jae Seok Bae Source Type: research
IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas
Nature Reviews Clinical Oncology, Published online: 21 March 2024; doi:10.1038/s41571-024-00885-zIL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 21, 2024 Category: Cancer & Oncology Authors: David Killock Source Type: research
A new standard of care for advanced-stage urothelial carcinoma
Nature Reviews Clinical Oncology, Published online: 20 March 2024; doi:10.1038/s41571-024-00884-0A new standard of care for advanced-stage urothelial carcinoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 20, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges
Nature Reviews Clinical Oncology, Published online: 20 March 2024; doi:10.1038/s41571-024-00882-2The composition of the gut microbiota has emerged as a tumour-extrinsic factor that modulates response to immune-checkpoint inhibitors (ICIs), although the lack of consistency in microbiota signatures across studies has limited their value as reliable biomarkers. Herein, we discuss a recent study in which longitudinal microbiome profiling identified several taxa that are persistently enriched in patients with melanoma and a favourable response to ICIs. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 20, 2024 Category: Cancer & Oncology Authors: Saman Maleki Vareki Diwakar Davar Source Type: research
Claudin 18.2 as a novel therapeutic target
Nature Reviews Clinical Oncology, Published online: 19 March 2024; doi:10.1038/s41571-024-00874-2The development and successful phase III testing of the anti-claudin 18.2 antibody zolbetuximab has provided a novel targeted therapy for the 30–40% of patients with strongly claudin 18.2-positive gastric cancers. Furthermore, the development of an effective targeted therapy for a target that does not have a driver role in cancer development provides a novel drug development paradigm. In this Review, the authors describe the development of claudin 18.2-targeted therapies, including zolbetuximab, as well as novel therapies, in...
Source: Nature Reviews Clinical Oncology - March 19, 2024 Category: Cancer & Oncology Authors: Izuma Nakayama Changsong Qi Yang Chen Yoshiaki Nakamura Lin Shen Kohei Shitara Source Type: research
